Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 3/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GJA1 | P17302 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltose SCHEMBL5568974 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL24202679 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL20553487 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21206262 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL23752618 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL23708014 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL24662526 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL25382543 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21511124 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL23467170 | 0.98 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-220819605-U | Gas filtering device of expiration detector | 深圳市中核海得威生物科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4162808-A1 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | DSM IP Assets B.V. (NL) | 2023-04-12 | — | — | EP | disclosed |
| US-20220047646-A1 | COMPOSITIONS FOR MANAGEMENT OF DISORDERS OF THE GASTROINTESTINAL TRACT | PANTHERYX, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220000891-A1 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | DSM IP ASSETS B.V. (NL) | 2022-01-06 | — | — | US | disclosed |
| CN-113631046-A | Methods of supporting gastrointestinal homeostasis | 帝斯曼知识产权资产管理有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3876750-A1 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | disclosed |
| US-10800893-B2 | Lactose-derived hydrogels and methods of producing the same | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200253933-A1 | METHODS FOR TREATING DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME | REDHILL BIOPHARMA LTD. (IL) | 2020-08-13 | — | — | US | disclosed |
| US-20200188326-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR MVID AND RELATED DISEASES | VANESSA RESEARCH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10668050-B2 | Compositions, methods and kits for treating diarrhea-predominant irritable bowel syndrome | REDHILL BIOPHARMA LTD. (IL) | 2020-06-02 | — | — | US | disclosed |
| US-9675588-B2 | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms | REDHILL BIOPHARMA LTD. (IL) | 2017-06-13 | — | — | US | disclosed |
| EP-3116500-A2 | ONDANSETRON EXTENDED RELEASE SOLID DOSAGE FORMS FOR TREATING EITHER NAUSEA, VOMITING OR DIARRHEA SYMPTOMS | Redhill Biopharma Ltd (IL) | 2017-01-18 | — | — | EP | disclosed |
| US-20150258029-A1 | ONDANSETRON EXTENDED RELEASE SOLID DOSAGE FORMS FOR TREATING EITHER NAUSEA, VOMITING OR DIARRHEA SYMPTOMS | REDHILL BIOPHARMA LTD. (IL) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136377-A2 | ONDANSETRON EXTENDED RELEASE SOLID DOSAGE FORMS FOR TREATING EITHER NAUSEA, VOMITING OR DIARRHEA SYMPTOMS | REDHILL BIOPHARMA LTD. (IL) | 2015-09-17 | — | — | WO | disclosed |
| US-20120186999-A1 | ELECTROCHEMICAL SENSOR | KANICHI RESEARCH SERVICES LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2425243-A2 | ELECTROCHEMICAL SENSOR | Kanichi Research Services Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20110104689-A1 | Single nucleotide polymorphisms and the identification of lactose intolerance | TISHKOFF SARAH A | 2011-05-05 | — | — | US | disclosed |
| WO-2010125333-A2 | ELECTROCHEMICAL SENSOR | KANICHI RESEARCH SERVICES LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20080220429-A1 | Single nucleotide polymorphisms and the identification of lactose intolerance | NATIONAL SCIENCE FOUNDATION | 2008-09-11 | — | — | US | disclosed |
| WO-2008057265-A2 | SINGLE NUCLEOTIDE POLYMORPHISMS AND THE IDENTIFICATION OF LACTOSE INTOLERANCE | UNIVERSITY OF MARYLAND (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104689-A1 | Single nucleotide polymorphisms and the identification of lactose intolerance | LCT, GALNT14, LCLAT1 | LGALS8 389/4885LGALS3 299/4885LGALS4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.